CAMBRIDGE, Mass., April 7, 2011 /PRNewswire/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment
of human viral diseases, today announced that it has commenced an
underwritten registered public offering of shares of its common
stock. All of these shares are being sold by Idenix.
J.P. Morgan Securities LLC is acting as sole book-running
manager and underwriter for the offering. Idenix intends to grant
the underwriter a 30-day option to purchase up to an additional 15
percent of the amount sold to cover over-allotments, if any. The
offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the final size or terms of the offering.
The shares will be issued pursuant to a shelf registration
statement on Form S-3 previously filed with and declared effective
by the Securities and Exchange Commission. Idenix has also
filed with the Securities and Exchange Commission a preliminary
prospectus supplement with respect to the offering.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy any securities of Idenix, nor shall
there be any offer or sale of securities in any state or
jurisdiction in which an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Copies of the
preliminary prospectus supplement and accompanying prospectus may
be obtained from J.P. Morgan Securities LLC via Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free
(866) 803-9204.
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical company engaged in the discovery and development
of drugs for the treatment of human viral diseases. Idenix's
current focus is on the treatment of infections caused by hepatitis
C virus.
Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033
(media)
Eric Hoffman (617) 224-4485
(investors)
SOURCE Idenix Pharmaceuticals, Inc.